State governments are changing the coverage of some injectable biologics in their prescription drug programs.
People who use many expensive injectable drugs to treat conditions like rheumatoid arthritis, multiple sclerosis, and diabetes are forced to switch to generic drugs to maintain coverage.
Drugs include Copaxone, Enbrel, Humalog, Humira, Lantus, Labnox, Novorapid, Remicade, and Rituxan.
Generic versions of biologics have undergone an extensive approval process by Health Canada, ensuring they are as safe and effective as branded drugs, according to the province.
People using the listed medicines will be switched to generic brands by March 31, 2024. Patients will receive a letter from the government with transition information.
By switching to cheaper treatments, the government says it can invest in other medicines and expand its prescription drug program.
